08:00 , Mar 4, 2013 |  BC Week In Review  |  Financial News

Actinobac completes venture financing

Actinobac Biomed Inc., North Brunswick, N.J.   Business: Cancer, Autoimmune   Date completed: 2/21/13   Type: Venture financing   Raised: $100,000   Investor: Foundation Venture Capital Group   ...
07:00 , Apr 12, 2012 |  BC Innovations  |  Targets & Mechanisms

DEL1: taking the bite out of periodontitis

An international team of researchers has used the endothelial protein DEL1 to treat periodontitis in mice.1 Despite the therapeutic angle, the near-term utility of DEL1 is more likely to be as a diagnostic and risk...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

Actinobac preclinical data

In leukemia cell lines in vitro, Leukothera plus etoposide, mitoxantrone, daunorubicin, busulfan or imatinib resulted in a synergistic increase in cytotoxicity vs. any of the compounds alone. Leukothera is an Aggregatibacter actinomycetemcomitans-derived leukotoxin that binds...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Clinical News

Actinobac preclinical data

In a mouse xenograft model of psoriasis, Leukothera significantly reduced clinical psoriasis scores and epidermal thickness from baseline to week 3 vs. vehicle-treated controls (p<0.001 and p=0.002, respectively). The Aggregatibacter actinomycetemcomitans-derived leukotoxin binds to ...